Comprehensive lung injury pathology induced by mTOR inhibitors

Clinical and Translational Oncology

Volumn 11, Issue 8, 2009, Pages 499-510

  Aparicio, Guadalupe ^a   Calvo, Moisés B ^b   Medina, Vanessa ^a   Fernández, Ovidio ^b   Jiménez, Paula ^c   Lema, Martina ^b   Figueroa, Angélica ^b   Aparicio, Luis M Antón ^b  

^a Oncology Research Lab INIBIC   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Interstitial lung disease; Pulmonary fi brosis; Rapamycin; ROS; Sirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ARTICLE; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; HUMAN; LUNG; LUNG FIBROSIS; LUNG INJURY; METABOLISM; PATHOLOGY;

HUMANS; LUNG; LUNG INJURY; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PULMONARY FIBROSIS; REACTIVE OXYGEN SPECIES;

EID: 74049151210     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0394-y     Document Type: Article

References (81)

1. Abraham RT (2004) PI3-kinase related kinases: "big" players in stress-induced signalling pathways. DNA Repair (Amst) 3:883-887
2. Chen J, Zheng XF, Brown EJ, Schreiber SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin- associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92:4947-4951
3. Jacinto E, Loewith R, Schmidt A et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128
4. Sarbassov DD, Ali SM, Kim DH et al (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302
5. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 91:1420-1424
6. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918
7. Duran I, Siu LL, Oza AM et al (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875-1880
8. Morelon E, Stern M, Kreis H (2000) Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343:225-226
9. Morelon E, Manzer-Bruneel MF, Peraldi MN, Kreis H (2001) Sirolimus; a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 16:18-20
10. Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77:1215-1220
11. Singer SJ, Tiernan R, Sullivan EJ (2000) Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343:1815-1816
12. Mahalati K (2000) Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 69:1581
13. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537
14. Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322
15. Galanis E, Buckner JC, Maurer MJ et al North Central Cancer Treatment Group (2005) Phase II trial of emsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304
16. Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent Temsirolimus (CCI-779) for relapse mantle cell lymphoma. J Clin Oncol 23:5347-5356
17. Israel-Biet D, Labrune S, Huchon GJ (1991) Drug-induced lung disease: Review, 1990. Eur Respir J 4:465-478
18. Kilburn KH (1980) Pulmonary disease induced by drugs. In: Fishman AP (ed.) Pulmonary disease and disorders. McGraw-Hill, New York, pp 707-724
19. Rosenow EC, Myers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease: An update. Chest 102:239-250
20. Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133:528-538
21. Weis RB, Muggia FM (1980) Cytotoxic druginduced pulmonary disease: Update. Am J Med 68:259-266
22. Whimster WF, de Poitiers W (1982) The lung. In: Riddell RH (ed.) Pathology of drug-induced and toxic diseases. Churchill Livingstone, New York, pp 167-200
23. Katzebstein ALA (1985) Pathogenesis of "fibrosis" in interstitial pneumonia: An electron microscopic study. Hum Pathol 16:1015-1024
24. Crystal RG, Bitterman PB, Rennard SI et al (1984) Interstitial lung disease of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 310:154-166
25. Rennard S, Bitterman P, Crystal R (1983) Response of the lower respiratory tract to injury. Mechanisms of repair of the parenchymal cells of the alveolar wall. Chest 84:735-739
26. Liebow A (1975) Defi nition and classification of interstitial pneumonia in human pathology. Prog Respir Res 8:1-33
27. Spencer H (1975) Pathogenesis of interstitial fibrosis of the lung. Prog Respir Res 8:34-44
28. Hussain SP, Hofseth LJ, Haris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276-285
29. Ohshima H, Tatemichi M, Sawa T (2003) Chemical basis of infl ammation-induced carcinogenesis. Arch Biochem Biophys 417:3-11
30. Chen LF, Williams SA, Mu Y et al (2005) NFkappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 25:7966-7975
31. Kiernan R (2003) Post-activation turn-off NFkappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278:2758-2766
32. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071
33. Ghosh S, Karin M (2002) Missing pieces in the NF-kB puzzle. Cell 109:S81-96
34. Hoffmann A, Levchenko A, Scott ML, Baltimore D (2002). The IkappaB-NF-kappaB signalling module: Temporal control and selective gene activation. Science 298:1241-1245
35. Hoffmann A, Leung TH, Baltimore D (2003) Genetic analysis of NF-kappaB/rel transcription factors defines functional specificities. EMBO J 22:5530-5539
36. Jacobs MN, Harrison SD (1998) Structure of an I-kBa/NF-kB complex. Cell 95:749-758
37. Chen LW, Egan L, Li ZW et al (2003) The two faces of IKK and NF-kappaB inhibition: Prevention of systemic infl ammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 9:575-581
38. Li Q, Verma IM (2002) NF-kB regulation in the immune system. Nat Rev Immunol 2:725-734
39. Maeda S, Chang L, Li ZW et al (2003) IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNF alpha. Immunity 19:725-737
40. Moore KJ, Rosen ED, Fitzgerald ML et al (2001) The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47
41. Petersen KF, Dufour S, Befroy D et al (2004) Impaired mitochondrial activity in the insulinresistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671
42. Castranova VD, Porter L, Millecchia JY et al (2002) Effect of inhaled crystalline silica in rat model: Time course of pulmonary reactions. Mol Cell Biochem 234-235:177-184
43. Shukla A, Ramos-Nino M, Mossman B (2003) Cell signalling and transcription factor activation by asbestos in lung injury and disease. Int J Biochem Cell Biol 35:1198-1209
44. Arslan SO, Zerin M, Vural H, Coskun A (2002) The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. J Pineal Res 32:21-25
45. Chen J, Stubbe J (2004) Bleomycins: A new methods will allow reinvestigation of old issues. Curr Opin Cell Biol 8:175-181
46. Hubbard AK, Timblin CR, Shukla A et al (2002) Activation of NF-kB-dependent gene expression by silica in lungs of luciferase reporter mice. Am J Physiol Lung Cell Mol Physiol 282:L968-975
47. Benjamin RC, Gill DM (1980) Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strands breaks. J Biol Chem 255:10502-10508
48. Cosi C, Marien M (1999) Implication of poly(ADP-ribose)polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann NY Acad Sci 890:227-239
49. Virag L (2005) Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 52:83-92
50. Fattman CL, Chang LY, Termin TA et al (2003) Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 35:763-771
51. Griffi th OW, Stuehr DJ (1995) Nitric oxide synthase: Properties and catalytic mechanism. Annu Rev Physiol 57:707-736
52. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 411:157-160
53. Adamsson IY, Bowden DH (1974) The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77:185-197
54. Fasske E, Morgenroth K (1983) Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis. Lung 161:133-146
55. Chakrabarti S, Makrigiorgos GM, O'Brien K et al (1996) Measurement of hydroxyl radicals catalyzed in the immediate vicinity of DNA by metal-bleomycin complexes. Free Radic Biol Med 20:777-783
56. Conley NS, Yarbro JW, Ferrari HA, Zeidler RB (1986) Bleomycin increases superoxide anion generation by pig peripheral alveolar macrophages. Mol Pharmacol 30:48-52
57. Tarnell EW, Oliver BL, Johnsson GM et al (1992) Superoxide anion production by rat neutrophils at various stages of belomycin-induced lung injury. Lung 170:41-50
58. Moncada S, Palmer RM, Higgs EA (1989) Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 38:1709-1715
59. Forstermann U, Gath I, Schwarz P et al (1995) Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 50:1321-1332
60. Cuzzocrea S, Zingarelli B, Hake P et al (1998) Antiinflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of infl ammation. Free Radic Biol Med 24:450-459
61. Wei XD, Charles IG, Smith A et al (1995) Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408-411
62. Gansauge S, Gansauge F, Nussler AK et al (1997) Exogenous, but not endogenous, nitric oxide increases proliferation rates in senescent human fibroblasts. FEBS Lett 410:160-164
63. Romanska HM, Polak JM, Colemena RA et al (2002) iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. J Pathol 197:372-379
64. Saleh D, Barnes PJ, Giaid A (1997) Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:1763-1769
65. Ask K, Maretin GE, Kolb M, Gauldie J (2006) Targeting genes for treatment in idiopathic pulmonary fibrosis: Challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 3:389-393
66. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B (1987). Some recent advances in the chemistry and biology of transforming growth factor-ß. J Cell Biol 105:1039-1045
67. Fine A, Goldstein RH (1987) The effect of transforming growth factor-ß on cell proliferation and collagen formation by lung fibroblasts. J Biol Chem 262:3897-3902
68. Moses HL, Branum EL, Proper JA, Robinson RA (1981) Transforming growth factor production by chemically transformed cells. Cancer Res 41:2842-2848
69. Roberts AB, Lamb LC, Newton DL et al (1980) Transforming growth factors: Isolation of polypeptides from virally and chemical transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 77:3494-3498
70. Gotzman J, Mikula M, Eger A et al (2004) Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis. Mutat Res 566:9-20
71. Tosh D, Slack JM (2002) How cells changes their phenotype. Nat Rev Mol Cell Biol 3:187-194
72. Roberts AB, Sporn MB (1993) Physiological actions and clinical applications of transforming growth factor-ß (TFG-ß). Growth Factors 8:1-9
73. Janda E, Lehmann K, Killisch I et al (2002) Ras and TGF(beta) cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signalling pathways. J Cell Biol 156:299-313
74. Peinado H, Quintanilla M, Cano A (2003) Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transition. J Biol Chem 278:21113-21123
75. Hoyt DG, Lazo JS (1988) Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-ß precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther 246:765-771
76. Barral-Neto M, Barral A, Brownel CE et al (1992) Transforming growth factor ß in leishmanial infection: A parasite escape mechanism. Science 257:545-548
77. Zhang K, Rekhter MD, Gordon D, Phan SH (1994) Localization of myofibroblasts in the lung, and their role in collagen gene expression in a model of pulmonary fibrosis. Am J Pathol 145:114-125
78. Li MO, Wan YY, Sanjabi S et al (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146
79. Rubtsov YP, Rudensky AY (2007) TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7:443-453
80. Khalil N, Corne S, Whitman C, Yacyshyn H (1996) Plasmin regulates the activation of cell-associated latent TGF-ß secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Resp Cell Mol Biol 15:252-259
81. Broekelmann TJ, Limper AH, Colby TV, McDonald JA (1991) Transforming growth factor ß1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 88:6642-6646